23. Oberlin E, Tavian M, Blazsek I, Peault B (2002) Blood-forming potential of vascular endothelium in the human embryo. Development 129: 4147–4157. 24. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G (1998) A common precursor for hematopoietic and endothelial cells. Development 125: 725–732. 25. Ueno H, Weissman IL (2006) Clonal analysis of mouse development reveals a polyclonal origin for yolk sac blood islands. Developmental Cell 11: 519–533. 26. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK (2006) Primary prevention of cardiovascular diseases with statin therapy: A meta-analysis of randomized controlled trials. Arch Intern Med 166: 2307–2313. 27. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. (2004) Intensive versus moderate lipid lowereing with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504. Statins, EPCs, and Capillary Density 28. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. (2005) Intensive lipid lowering with Atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–35. 29. Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105: 739–745. 30. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD (2009) Molecular basis of statin-associated myopathy. Atherosclerosis 202: 18–28. 31. Mason RP, Walter MF, Day CA, Jacob RF (2005) Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotrophic actions. Am J Cardiol 96: 11F–23F. 32. Dubois C, Liu X, Claus P, Marsboom G, Pokreisz P, et al. (2010) Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction. J Am Coll Cardiol- ogy 55: 2232–43. PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24868